That 33% jump in stock price needs a little context. Puma Biotechnology is still valued at just $350 million even after those gains. In other words, it was probably a little easier for investors to ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Adam Feuerstein is a senior writer and ...

SAN ANTONIO, May 26, 2022 /PRNewswire/ -- CorePath is excited to announce a partnership with Cizzle Biotechnology, a UK based diagnostics developer, to develop and offer a proprietary early-stage lung ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...